Avecho Biotechnology Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AVE.AX | NTRB | 18H0.F | HRTX | ALGS | IBO | |
|---|---|---|---|---|---|---|
| Market cap | 50.23M | 73.91M | 5.11M | 56.69M | 31.35M | 35.42M |
| P/E (TTM) | — | — | — | — | — | 0.4 |
| Forward P/E | — | -26.4 | — | -2.7 | -1.0 | — |
| Price/book | — | 13.9 | -1.1 | 9.6 | 1.0 | 3.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +116.67% | +9.95% | −25.00% | −74.77% | −29.30% | −39.34% |
| Today | 0.00% | −3.34% | −23.81% | +4.88% | +5.68% | +1.99% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All AVE.AX news ›Why Avecho Biotechnology (ASX:AVE) reported cash and a restarted Phase III insomnia trial recruitment push
Sayona Mining (ASX:SYA): Can Operational Changes Weather Weak Prices? The company, which is developing a CBD soft-gel capsule for insomnia using its TPM drug-delivery technology, also said recruitment has restarted for the final cohort of…
Avecho Biotechnology Limited (ASX:AVE): Phosphorylated Vitamin E Technology and Oral Drug Delivery
For Avecho Biotechnology Limited (ASX:AVE), the distinction between a technology’s intended function and demonstrated outcomes is important. Product-specific evidence is required before general technical claims can be treated as validated…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- kalkinemedia.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.